Eiger BioPharmaceuticals, Inc. 72C1.F Stock
Eiger BioPharmaceuticals, Inc. Price Chart
Eiger BioPharmaceuticals, Inc. 72C1.F Financial and Trading Overview
| Eiger BioPharmaceuticals, Inc. stock price | 0.21 EUR |
| Previous Close | 0.86 EUR |
| Open | 0.88 EUR |
| Bid | 0.88 EUR x 100000 |
| Ask | 0.91 EUR x 100000 |
| Day's Range | 0.88 - 0.88 EUR |
| 52 Week Range | 0.77 - 9.37 EUR |
| Volume | 180 EUR |
| Avg. Volume | 195 EUR |
| Market Cap | 41.31M EUR |
| Beta (5Y Monthly) | 1.890218 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29 EUR |
72C1.F Valuation Measures
| Enterprise Value | 2.49M EUR |
| Trailing P/E | N/A |
| Forward P/E | -0.48611113 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.7670784 |
| Price/Book (mrq) | 1.0992463 |
| Enterprise Value/Revenue | 0.167 |
| Enterprise Value/EBITDA | -0.027 |
Trading Information
Eiger BioPharmaceuticals, Inc. Stock Price History
| Beta (5Y Monthly) | 1.890218 |
| 52-Week Change | -81.89% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9.37 EUR |
| 52 Week Low | 0.77 EUR |
| 50-Day Moving Average | 0.97 EUR |
| 200-Day Moving Average | 2.95 EUR |
72C1.F Share Statistics
| Avg. Volume (3 month) | 195 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 44.3M |
| Float | 35.16M |
| Short Ratio | N/A |
| % Held by Insiders | 11.43% |
| % Held by Institutions | 61.09% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -624.17% |
| Gross Margin | 87.64% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -46.11% |
| Return on Equity (ttm) | -146.28% |
Income Statement
| Revenue (ttm) | 14.93M EUR |
| Revenue Per Share (ttm) | 0.34 EUR |
| Quarterly Revenue Growth (yoy) | 54.10% |
| Gross Profit (ttm) | 11.65M EUR |
| EBITDA | -92890000 EUR |
| Net Income Avi to Common (ttm) | -96917000 EUR |
| Diluted EPS (ttm) | -1.95 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 80.02M EUR |
| Total Cash Per Share (mrq) | 1.81 EUR |
| Total Debt (mrq) | 40.43M EUR |
| Total Debt/Equity (mrq) | 114.72 EUR |
| Current Ratio (mrq) | 4.038 |
| Book Value Per Share (mrq) | 0.796 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -88556000 EUR |
| Levered Free Cash Flow (ttm) | -54136248 EUR |
Profile of Eiger BioPharmaceuticals, Inc.
| Country | Germany |
| State | CA |
| City | Palo Alto |
| Address | 2155 Park Boulevard |
| ZIP | 94306 |
| Phone | 650 272 6138 |
| Website | https://www.eigerbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 51 |
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Q&A For Eiger BioPharmaceuticals, Inc. Stock
What is a current 72C1.F stock price?
Eiger BioPharmaceuticals, Inc. 72C1.F stock price today per share is 0.21 EUR.
How to purchase Eiger BioPharmaceuticals, Inc. stock?
You can buy 72C1.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Eiger BioPharmaceuticals, Inc.?
The stock symbol or ticker of Eiger BioPharmaceuticals, Inc. is 72C1.F.
Which industry does the Eiger BioPharmaceuticals, Inc. company belong to?
The Eiger BioPharmaceuticals, Inc. industry is Biotechnology.
How many shares does Eiger BioPharmaceuticals, Inc. have in circulation?
The max supply of Eiger BioPharmaceuticals, Inc. shares is 1.56M.
What is Eiger BioPharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Eiger BioPharmaceuticals, Inc. PE Ratio is 0.00000000 now.
What was Eiger BioPharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Eiger BioPharmaceuticals, Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Eiger BioPharmaceuticals, Inc. company belong to?
The Eiger BioPharmaceuticals, Inc. sector is Healthcare.